Brief: ORIC Pharmaceuticals Q2 Net Income USD -36.355 Million

ORIC Pharmaceuticals

12/08/2025 21:05

Overview

ORIC Pharmaceuticals Q2 net loss $36.4 mln, basic EPS misses expectations at -$0.47

Company strengthens cash position with $244 mln from recent financings

ORIC prioritizes clinical programs, reducing discovery research investment

Outlook

ORIC expects cash runway to extend into 2H 2028

Company plans to initiate registrational trials for ORIC-944 and ORIC-114 in 2026

ORIC anticipates primary endpoint readouts from Phase 3 trials before 2H 2028

Company revises operating plan to focus on clinical programs

Result Drivers

STRATEGIC FOCUS - ORIC prioritizes clinical programs, reducing investment in discovery research and implementing workforce reduction

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$36.36 mln
Q2 Basic EPS
Miss
-$0.47
-$0.44 (10 Analysts)
Q2 Income from Operations
-$39.06 mln
Q2 Operating Expenses
$39.06 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $19.00, about 51.6% above its August 11 closing price of $9.20

Press Release: ID:nGNXcdy0YT

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)